ライフサイエンスコーパス: placental growth factor

1 GFR family, and binds to VEGF-A, VEGF-B, and placental growth factor.

2 lt1), an antiangiogenic protein, relative to placental growth factor.

3 -1alpha, the angiopoietin receptor Tie2, and placental growth factor.

4 st of vascular endothelial growth factor and placental growth factor.

5 r, vascular endothelial growth factor165, or placental growth factor.

6 r stimulated with a VEGFR-1-specific ligand, placental growth factor 1.

7 ve VEGF receptors, binds VEGF-A, VEGF-B, and placental growth factors 1 and 2 with high affinity.

8 eceptor-2 (R2), whereas the VEGFR1 agonists, placental growth factors 1 and 2, had no effect on FABP4

9 ndlimb ischemia and to examine the effect of placental growth factor-1 (PlGF-1) on this process.

10 The VEGFR-1-specific ligand placental growth factor-1 (PlGF-1), but not VEGF-E, whic

11 Placental growth factor-1 (PlGF-1), which exclusively bi

12 arged peptide derived from the C-terminus of placental growth factor-2 (PLGF-2) was selected to enhan

13 VEGF and placental growth factor affect the early stages of myelo

14 s of the VEGF family, VEGF-A through VEGF-E, placental growth factor and the newly described, tissue-

15 , and Ki-67 using immunohistochemistry; with placental growth factor and vascular endothelial growth

16 Using selective ligands (VEGF-E and placental growth factor) and a receptor-specific inhibit

17 human chorionic gonadotropin, progesterone, placental growth factor, and placental lactogen.

18 nic factors angiopoietin-1 (ANGPT1), ANGPT2, placental growth factor, and platelet-derived growth fac

19 ine chromogranin A, neuron-specific enolase, placental growth factor, and soluble vascular endothelia

20 opoietin, platelet-derived growth factor-BB, placental growth factor, and vascular endothelial growth

21 1, ANGPT2, platelet-derived growth factor-B, placental growth factor, and VEGF mRNA in AdCA5-injected

22 Changes in plasma placental growth factor, basic fibroblast growth factor,

23 ctors soluble fms-like tyrosine kinase 1 and placental growth factor, both biomarkers associated with

24 vascular endothelial growth factor (VEGF) or placental growth factor-critical regulators of tumour an

25 fusion protein that scavenges both VEGF and placental growth factor in patients with recurrent malig

26 tor (not bound to bevacizumab) and increased placental growth factor in plasma.

27 Placental growth factor increased, whereas endoglin and

28 ta growth factor levels are high in SCD, and placental growth factor induces the release of the vasoc

29 eased vascular endothelial growth factor and placental growth factor levels and intrauterine growth r

30 Neither placental growth factor nor an Flt-1-selective variant w

31 .046), hepatocyte growth factor (P = .046), placental growth factor (P < .001), stromal-derived fact

32 correlated significantly with an increase in placental growth factor (P = .003) and a decrease in sol

33 BCCs and MSCs expressed placental growth factor (PGF) and its cognate receptor V

34 ify the pro-proliferative VEGF family member placental growth factor (PGF) as an aldosterone-regulate

35 mbers VEGFA, VEGFB, VEGFC, VEGFD (FIGF), and placental growth factor (PGF); VEGF receptors VEGFR1 (FL

36 cluding angiopoietin 2, angiopoietin-like 4, placental growth factor, platelet-derived growth factor

37 in the expression of the angiogenic factors placental growth factor, platelet-derived growth factor

38 These findings reveal that placental growth factor plays a critical role in the con

39 VEGF-B and placental growth factor (PlGF) activate VEGFR-1 selectiv

40 We sought to evaluate placental growth factor (PlGF) and soluble Fms-like tyro

41 like tyrosine kinase 1 (sFlt-1), which binds placental growth factor (PlGF) and vascular endothelial

42 Placental growth factor (PlGF) and vascular endothelial

43 ascular endothelial growth factor (VEGF) and placental growth factor (PlGF) are increased in sepsis.

44 ascular endothelial growth factor (VEGF) and placental growth factor (PLGF) are increased in the mate

45 tyrosine kinase 1 (sFlt1) and proangiogenic placental growth factor (PlGF) at presentation and exami

46 dverse events (AEs), and association between placental growth factor (PLGF) change and OS.

47 ell growth factor (VEGF) homodimers and VEGF/placental growth factor (PlGF) heterodimers.

48 ascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in animal and human model

49 d the mRNA expression of VEGF receptor-1 and placental growth factor (PLGF) in HEECs.

50 The role of placental growth factor (PlGF) in modulation of tumor an

51 ed transgenic, conditional overexpression of placental growth factor (PlGF) in murine cardiac tissues

52 ution of isoforms of VEGF and of the related placental growth factor (PlGF) in the body and resulting

53 Placental growth factor (PlGF) is a critical mediator of

54 Placental growth factor (PlGF) is a member of the proang

55 Placental growth factor (PlGF) is a member of the vascul

56 Placental growth factor (PlGF) is an angiogenic factor,

57 luble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant w

58 Here, we report that placental growth factor (PlGF) is expressed in the major

59 and treatment study was set up, blocking the placental growth factor (PlGF) or vascular endothelial g

60 Placental growth factor (PlGF) remodels tumor vasculatur

61 labeling with anti-PECAM1 antibody and anti-placental growth factor (PlGF) showed high levels of PlG

62 flk-1 kinase inhibitor SU1498 and failure of placental growth factor (PlGF) to up-regulate DAF confir

63 Up-regulation of placental growth factor (PlGF), a member of the vascular

64 evidence that a monoclonal antibody against placental growth factor (PlGF), a member of the VEGF fam

65 se 1 (sFlt1), an antiangiogenic protein, and placental growth factor (PlGF), a proangiogenic protein,

66 mbined with microarray analysis, to identify Placental Growth Factor (PlGF), a Vascular Endothelial G

67 pported by our finding that tumor-associated placental growth factor (PlGF), a VEGFR1-specific agonis

68 Placental growth factor (PlGF), abundantly produced from

69 EGF), basic fibroblast growth factor (bFGF), placental growth factor (PlGF), and monocyte chemoattrac

70 ved, but the precise role of VEGF-A, VEGF-B, placental growth factor (PlGF), and their receptors VEGF

71 kinase 1 (sFlt1), an antagonist of VEGF and placental growth factor (PlGF), is upregulated in preecl

72 whereas B16F10 cells secrete high levels of placental growth factor (PLGF), LLC cells produce high l

73 showed that cardiac angiogenesis induced by placental growth factor (PlGF), promotes myocardial hype

74 tion factor (GDF)-15, myeloperoxidase (MPO), placental growth factor (PlGF), soluble fms-like tyrosin

75 ated dilatation, and serum concentrations of placental growth factor (PlGF), soluble fms-like tyrosin

76 in early gestation expressed VEGF-A, VEGF-C, placental growth factor (PlGF), VEGFR-1, and VEGFR-3 and

77 Placental growth factor (PlGF), which signals through VE

78 thelial growth factor (VEGF)-related factor, placental growth factor (PlGF),has been shown recently t

79 diates cell migration in response to VEGF or placental growth factor (PLGF).

80 luble fms-like tyrosine kinase 1 (sFlt1) and placental growth factor (PlGF)] in predicting short-term

81 EGF-C, soluble VEGF receptor [sVEGFR]-3, and placental growth factor [PlGF]) levels were measured.

82 tio of soluble fms-like tyrosine kinase 1 to placental growth factor positively correlated with blood

83 known as Flt1)-cognate receptor for VEGF and placental growth factor-prevented BMDC infiltration in l

84 On cytokine profiling, LDA increased placental growth factor production and selectively resto

85 esponse 1, soluble guanylate cyclase 1A3 and placental growth factor protein.

86 otein/creatinine ratio >0.30 g/g, and sFlt-1/placental growth factor ratio >85).

87 xogenous VEGF or the VEGFR1-specific ligand, placental growth factor, revealed distinct roles of VEGF

88 ngiopoietin 2, interleukin 6, interleukin 8, placental growth factor, soluble TIE-1, soluble VEGFR1,

89 sVEGFR2 showed the largest decrease, whereas placental growth factor underwent the largest increase.

90 r; platelet-derived growth factor AA and BB; placental growth factor; vascular endothelial growth fac

91 t only VEGF-A but also VEGF homologues (e.g. placental growth factor, VEGF-B, and VEGF-C), which may

92 tio of soluble fms-like tyrosine kinase 1 to placental growth factor was independently associated wit

93 Neither placental growth factor, which activates Flt1, epidermal

94 In contrast, overexpression of placental growth factor, which signals through Flt1 but

95 that binds all isoforms of VEGF-A as well as placental growth factor with high affinity, was administ